Bamco Inc. NY Purchases 5,500 Shares of Gilead Sciences, Inc. $GILD

Bamco Inc. NY lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 29.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 24,000 shares of the biopharmaceutical company’s stock after purchasing an additional 5,500 shares during the quarter. Bamco Inc. NY’s holdings in Gilead Sciences were worth $2,664,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Csenge Advisory Group boosted its stake in Gilead Sciences by 319.0% during the third quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company’s stock worth $2,375,000 after buying an additional 16,288 shares in the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its stake in shares of Gilead Sciences by 52.1% in the 3rd quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 78,494 shares of the biopharmaceutical company’s stock valued at $8,713,000 after buying an additional 26,882 shares in the last quarter. Cookson Peirce & Co. Inc. lifted its holdings in shares of Gilead Sciences by 249.1% during the 3rd quarter. Cookson Peirce & Co. Inc. now owns 10,045 shares of the biopharmaceutical company’s stock worth $1,115,000 after acquiring an additional 7,168 shares during the period. Railway Pension Investments Ltd lifted its holdings in shares of Gilead Sciences by 3.1% during the 3rd quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company’s stock worth $157,139,000 after acquiring an additional 42,200 shares during the period. Finally, TriaGen Wealth Management LLC acquired a new stake in shares of Gilead Sciences during the 3rd quarter valued at about $1,274,000. 83.67% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total value of $617,500.00. Following the completion of the transaction, the director directly owned 8,920 shares of the company’s stock, valued at $1,101,620. The trade was a 35.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $154.44, for a total transaction of $4,324,320.00. Following the transaction, the insider owned 120,288 shares in the company, valued at approximately $18,577,278.72. This trade represents a 18.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 303,280 shares of company stock worth $43,203,470 in the last three months. Company insiders own 0.27% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Morgan Stanley upped their target price on shares of Gilead Sciences from $150.00 to $171.00 and gave the company an “overweight” rating in a research note on Wednesday, February 11th. JPMorgan Chase & Co. lifted their price objective on Gilead Sciences from $150.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday, February 11th. Bank of America set a $162.00 price objective on Gilead Sciences and gave the company a “buy” rating in a research note on Wednesday, February 11th. Barclays started coverage on Gilead Sciences in a report on Friday, February 20th. They issued an “equal weight” rating and a $155.00 target price for the company. Finally, HSBC raised their target price on Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a research report on Wednesday, December 10th. Twenty-four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $157.62.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $145.21 on Tuesday. The firm has a market cap of $180.27 billion, a price-to-earnings ratio of 21.45, a PEG ratio of 1.90 and a beta of 0.36. The company has a 50 day moving average of $141.16 and a 200-day moving average of $127.19. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. Gilead Sciences, Inc. has a 1-year low of $93.37 and a 1-year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.83 by $0.03. The business had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.Gilead Sciences’s revenue was up 4.7% compared to the same quarter last year. During the same period in the previous year, the business earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be given a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.3%. The ex-dividend date is Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio is presently 48.45%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.